Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting extra-gonadal androgens in castration-resistant prostate cancer.

The Journal of steroid biochemistry and molecular biology - 1 Jan 2015

Grist Emily, de Bono Johann S, Attard Gerhardt

Abstract excerpt

Metastatic castration resistant prostate cancer (CRPC) is associated with a rise in PSA, suggesting an increase in transcription of steroid receptor regulated genes. The efficacy of the new anti-androgen therapies abiraterone and enzalutamide, that target extra-gonadal activation of androgen sign...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Receptor Antagonists
Share to Androgens
Share to Androstenes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzamides

Share to Nitriles

Share to Prostatic Neoplasms, Castration-Resistant

Share to Receptors, Androgen

Share to Steroids

Source

Identifiers

PMID: 25251387
DOI: 10.1016/j.jsbmb.2014.09.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25251387-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting extra-gonadal androgens in castration-resistant prostate cancer.PMID 25251387Read ↗

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.Semantic proximity Read ↗

Persistent androgen receptor addiction in castration-resistant prostate cancerSemantic proximity Read ↗

Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistanceSemantic proximity Read ↗

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanismsSemantic proximity Read ↗

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical ApplicationsSemantic proximity Read ↗

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approachesSemantic proximity Read ↗

Overcoming castration resistance in prostate cancer.Semantic proximity Read ↗

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistanceSemantic proximity Read ↗

Minireview: Androgen Metabolism in Castration-Resistant Prostate CancerSemantic proximity Read ↗

Targeting the androgen receptor and overcoming resistance in prostate cancerSemantic proximity Read ↗

Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.Semantic proximity Read ↗

Mechanisms of resistance to androgen deprivation therapy in prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.